Novel investigational agents for the treatment of scleroderma.
about
A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients.M10, a caspase cleavage product of the hepatocyte growth factor receptor, interacts with Smad2 and demonstrates antifibrotic properties in vitro and in vivo.Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures PerspectivesA new alternative therapy in dermatology: tocilizumab.Current and future direction in the management of scleroderma.Scleroderma-related interstitial lung disease.
P2860
Novel investigational agents for the treatment of scleroderma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Novel investigational agents for the treatment of scleroderma.
@en
type
label
Novel investigational agents for the treatment of scleroderma.
@en
prefLabel
Novel investigational agents for the treatment of scleroderma.
@en
P2860
P1476
Novel investigational agents for the treatment of scleroderma.
@en
P2093
Fredrick M Wigley
Zsuzsanna Hortobagyi McMahan
P2860
P304
P356
10.1517/13543784.2014.848852
P407
P577
2013-11-22T00:00:00Z